Other
Adjuvant Treatment
0
Pipeline Programs↗
14
Active Trials↗
4
Companies Involved↗
Adjuvant Treatment is an early-stage landscape with 0 programs across 4 companies. The most active players are Sanofi, Novartis, Roche.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
51
clinical trials
Completed15 · 29%
Unknown status15 · 29%
Recruiting7 · 14%
Terminated6 · 12%
Active, not recruiting4 · 8%
Not yet recruiting3 · 6%
Other1 · 2%
Clinical Trials
Trial Activity
51 trials
A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse
Recruiting·—·Phase 3·NCT06643585·180 enrolled
Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ
Recruiting·—·Phase 2·NCT06761846·70 enrolled
Mebendazole as Adjuvant Treatment for Colon Cancer
Recruiting·—·Phase 3·NCT03925662·40 enrolled
Alectinib in Neo-adjuvant Treatment of Stage III NSCLC
Active, not recruiting·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT05015010·33 enrolled
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
Active, not recruiting·—·Phase 3·NCT02215265·1,269 enrolled
Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC
Not yet recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT06439550·42 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)